Literature DB >> 12939566

The diagnosis and management of renovascular disease: a primary care perspective. Part II. Issues in management.

Michael J Bloch1, Jan Basile.   

Abstract

Renovascular disease is a complex disorder, most commonly caused by fibromuscular dysplasia and atherosclerotic disease. It usually presents in one of three forms: asymptomatic renal artery stenosis, renovascular hypertension, or ischemic nephropathy. This complexity may make diagnostic and management decisions difficult for the primary care physician. In Part I of this review (presented in the May/June 2003 issue of The JCH), the authors discussed when to consider and how to go about making a diagnosis of renovascular disease. In Part II, the authors review the management of this complex condition. There is a debate concerning the optimal treatment of patients with renovascular disease. Management options include medical, surgical, or percutaneous approaches (angioplasty and stenting). Generally in patients with fibromuscular disease, the results of surgery and percutaneous approaches appear superior. In patients with atherosclerotic disease, the data are less consistent, and there does appear to be a group of patients who will respond well to medical management. A potential management algorithm is presented.

Entities:  

Mesh:

Year:  2003        PMID: 12939566      PMCID: PMC8101816          DOI: 10.1111/j.1524-6175.2003.01811.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  45 in total

Review 1.  Epidemiology and clinical presentation.

Authors:  S C Textor
Journal:  Semin Nephrol       Date:  2000-09       Impact factor: 5.299

Review 2.  Diminished operative risk and improved results following revascularization for atherosclerotic renovascular disease.

Authors:  A C Novick; R B Khauli; D G Vidt
Journal:  Urol Clin North Am       Date:  1984-08       Impact factor: 2.241

3.  Comparative analysis of percutaneous transluminal angioplasty and operation for renal revascularization.

Authors:  L S Erdoes; S S Berman; G C Hunter; J L Mills
Journal:  Am J Kidney Dis       Date:  1996-04       Impact factor: 8.860

4.  Effect of renal artery stenting on renal function and size in patients with atherosclerotic renovascular disease.

Authors:  P S Watson; P Hadjipetrou; S V Cox; T C Piemonte; A C Eisenhauer
Journal:  Circulation       Date:  2000-10-03       Impact factor: 29.690

5.  Four-year follow-up of Palmaz-Schatz stent revascularization as treatment for atherosclerotic renal artery stenosis.

Authors:  G Dorros; M Jaff; L Mathiak; I I Dorros; A Lowe; K Murphy; T He
Journal:  Circulation       Date:  1998-08-18       Impact factor: 29.690

6.  Renal artery stent placement: long-term results with the Wallstent endoprosthesis.

Authors:  L M Hennequin; F G Joffre; H P Rousseau; R Aziza; P Tregant; P Bernadet; M Salvador; B Chamontin
Journal:  Radiology       Date:  1994-06       Impact factor: 11.105

7.  Percutaneous transluminal renal angioplasty versus surgical reconstruction of atherosclerotic renal artery stenosis: a prospective randomized study.

Authors:  H Weibull; D Bergqvist; S E Bergentz; K Jonsson; L Hulthén; P Manhem
Journal:  J Vasc Surg       Date:  1993-11       Impact factor: 4.268

8.  Treatment of atherosclerotic ostial renal artery stenosis with the intravascular stent.

Authors:  K R Tuttle; R F Chouinard; J T Webber; L R Dahlstrom; R A Short; K J Henneberry; L A Dunham; R D Raabe
Journal:  Am J Kidney Dis       Date:  1998-10       Impact factor: 8.860

9.  Treatment of renovascular hypertension with percutaneous transluminal dilatation of a renal-artery stenosis.

Authors:  A Grüntzig; U Kuhlmann; W Vetter; U Lütolf; B Meier; W Siegenthaler
Journal:  Lancet       Date:  1978-04-15       Impact factor: 79.321

10.  Comparison of effects of enalapril plus hydrochlorothiazide versus standard triple therapy on renal function in renovascular hypertension.

Authors:  S S Franklin; R D Smith
Journal:  Am J Med       Date:  1985-09-27       Impact factor: 4.965

View more
  1 in total

1.  Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies.

Authors:  Felix Mahfoud; Michel Azizi; Sebastian Ewen; Atul Pathak; Christian Ukena; Peter J Blankestijn; Michael Böhm; Michel Burnier; Gilles Chatellier; Isabelle Durand Zaleski; Guido Grassi; Michael Joner; David E Kandzari; Ajay Kirtane; Sverre E Kjeldsen; Melvin D Lobo; Thomas F Lüscher; John William McEvoy; Gianfranco Parati; Patrick Rossignol; Luis Ruilope; Markus P Schlaich; Atif Shahzad; Faisal Sharif; Andrew S P Sharp; Horst Sievert; Massimo Volpe; Michael A Weber; Roland E Schmieder; Costas Tsioufis; William Wijns
Journal:  Eur Heart J       Date:  2020-04-21       Impact factor: 29.983

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.